Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Adults and Children With Previously Untreated Patients With Aggressive Non-Hodgkin's Lymphoma.

Trial Profile

Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Adults and Children With Previously Untreated Patients With Aggressive Non-Hodgkin's Lymphoma.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Dec 2018

At a glance

  • Drugs Rituximab (Primary) ; Cyclophosphamide; Doxorubicin; Etoposide; Filgrastim; Prednisone; Vincristine
  • Indications Non-Hodgkin's lymphoma
  • Focus Pharmacogenomic; Therapeutic Use
  • Acronyms EPOCH
  • Most Recent Events

    • 31 Oct 2018 Planned primary completion date changed from 31 Mar 2019 to 31 Mar 2020.
    • 31 Oct 2018 Planned primary completion date changed from 31 Mar 2019 to 31 Mar 2020.
    • 16 Feb 2017 Status changed from suspended to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top